Nilotinib

Nilotinib is a targeted anticancer drug used mainly to treat chronic myeloid leukemia (CML). It is a tyrosine kinase inhibitor (TKI) that specifically blocks the BCR-ABL protein, an abnormal enzyme produced by the Philadelphia chromosome mutation found in CML patients. By inhibiting this enzyme, nilotinib helps stop the uncontrolled growth of cancerous white blood cells. It is typically used in patients who are newly diagnosed or who are resistant or intolerant to earlier treatments like imatinib. It is grouped under the following drug class(es): Antineoplastic agents, Kinase inhibitors, QTc-prolonging agents and Tyrosine Kinase Inhibitors. Its therapeutic use is listed as anti-cancer agents and antineoplastics. The directory classifies it as a commercial API with a synthetic source/manufacturing origin. Other names for this substance include nilotinibum and 4-Methyl-3-((4-(3-pyridinyl)-2-pyrimidinyl)amino)-N-(5-(4-methyl-1H-imidazol-1-yl)-3-(trifluoromethyl)phenyl)benzamide. Its PubChem CID is 644241.

CAS No 641571-10-0
Molecular Formula C28H22F3N7O
Molecular Weight 529.5 g/mol
Synonyms 4-methyl-N-[3-(4-methylimidazol-1-yl)-5-(trifluoromethyl)phenyl]-3-[(4-pyridin-3-ylpyrimidin-2-yl)amino]benzamide

Frequently Asked Questions